Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells

Kindt,Nadège; Laurent,Guy; Nonclercq,Denis; Journé,Fabrice; Ghanem,Ghanem; Duvillier,Hugues; Gabius,Hans-Joachim; Lechien,Jérôme; Saussez,Sven

doi:10.3892/ijo.2013.1944

Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells

Authors:
- Nadège Kindt
- Guy Laurent
- Denis Nonclercq
- Fabrice Journé
- Ghanem Ghanem
- Hugues Duvillier
- Hans-Joachim Gabius
- Jérôme Lechien
- Sven Saussez
View Affiliations

Affiliations: Laboratory of Anatomy and Cellular Biology, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium, Laboratory of Histology, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium, Laboratory of Oncology and Experimental Surgery, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Bruxelles, Belgium, Laboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Bruxelles, Belgium, Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig Maximillians University, D-80539 Munich, Germany
Published online on: May 16, 2013 https://doi.org/10.3892/ijo.2013.1944
Pages: 185-193

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent clinical observations and experimental studies of our group indicate that macrophage migration inhibitory factor (MIF) may contribute to tumor progression in head and neck squamous cell carcinomas (HNSCC). The present study was undertaken to examine the effects of the irreversible MIF inhibitor 4-iodo-6-phenylpyrimidine (4-IPP) on proliferation and invasiveness of the squamous carcinoma cell line SCCVII. Cell counting, crystal violet assay and flow cytometry were used to analyze the effects of 4-IPP on SCCVII cell growth. The impact of 4-IPP on cell invasiveness was assessed by Boyden chamber assay. Knockdown of the MIF receptor CD74 was achieved by transduction with lentiviral vectors encoding anti-CD74 shRNAs. As shown by immunofluorescence staining, SCCVII cells express both MIF and CD74. Decreased MIF immunoreactivity as a result of exposure to 4-IPP suggested a covalent modification of the cytokine. 4-IPP inhibited SCCVII cell proliferation and invasiveness. Moreover, the cytostatic effect of 4-IPP was enhanced by CD74 knockdown. The inhibitory effects of 4-IPP on cell proliferation and invasiveness strongly suggest that MIF is involved in proliferative activity and invasive properties of squamous carcinoma cells. In conclusion, MIF inhibition may open possibilities for target-directed treatment of head and neck squamous cell carcinoma.

View Figures

View References

1.	Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC and David JR: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA. 86:7522–7526. 1989. View Article : Google Scholar : PubMed/NCBI
2.	Sugimoto H, Suzuki M, Nakagawa A, Tanaka I and Nishihira J: Crystal structure of macrophage migration inhibitory factor from human lymphocyte at 2.1 A resolution. FEBS Lett. 389:145–148. 1996. View Article : Google Scholar : PubMed/NCBI
3.	Sun HW, Bernhagen J, Bucala R and Lolis E: Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA. 93:5191–5196. 1996. View Article : Google Scholar
4.	Kato Y, Muto T, Tomura T, Tsumura H, Watarai H, Mikayama T, Ishizaka K and Kuroki R: The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets. Proc Natl Acad Sci USA. 93:3007–3010. 1996. View Article : Google Scholar : PubMed/NCBI
5.	Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K and Bucala R: Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med. 1:781–788. 1995.PubMed/NCBI
6.	Flaster H, Bernhagen J, Calandra T and Bucala R: The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol. 21:1267–1280. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, Metz CN, Bucala R and Donnelly SC: Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest. 101:2869–2874. 1998. View Article : Google Scholar : PubMed/NCBI
8.	de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK and Terhorst C: Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2:1061–1066. 2001.PubMed/NCBI
9.	Morand EF, Leech M, Weedon H, Metz C, Bucala R and Smith MD: Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford). 41:558–562. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Foote A, Briganti EM, Kipen Y, Santos L, Leech M and Morand EF: Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 31:268–273. 2004.PubMed/NCBI
11.	Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW and Griffiths CE: Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol. 123:484–487. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, Leal E, Juárez I, Whitacre C, Kithcart A, Pruitt J, Sielecki T, Satoskar AR and Rodriguez-Sosa M: Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 24:2583–2590. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Chesney J, Metz C, Bacher M, Peng T, Meinhardt A and Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 5:181–191. 1999.PubMed/NCBI
14.	Zeng F-Y, Weiser WY, Kratzin H, Stahl B, Karas M and Gabius HJ: The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor? Arch Biochem Biophys. 303:74–80. 1993. View Article : Google Scholar : PubMed/NCBI
15.	Zeng FY, Gerke V and Gabius HJ: Characterization of the macrophage migration inhibitory factor-binding site of sarcolectin and its relationship to human serum albumin. Biochem Biophys Res Commun. 200:89–94. 1994. View Article : Google Scholar : PubMed/NCBI
16.	Kayser K, Bovin NV, Korchagina EY, Zeilinger C, Zeng FY and Gabius H-J: Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer. 30A:653–657. 1994. View Article : Google Scholar : PubMed/NCBI
17.	Meyer-Siegler K and Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 48:448–452. 1996. View Article : Google Scholar
18.	He XX, Yang J, Ding YW, Liu W, Shen QY and Xia HH: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006. View Article : Google Scholar
19.	Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H and Balkwill FR: Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cell Ther. 6:1993–2002. 2007.PubMed/NCBI
20.	He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR and Al-Abed Y: Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med. 15:1–10. 2009.PubMed/NCBI
21.	Krockenberger M, Engel JB, Kolb J, Dombrowsky Y, Häusler SF, Kohrenhagen N, Dietl J, Wischhusen J and Honig A: Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol. 136:651–657. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Kindt N, Lechien J, Decaestecker C, Rodriguez A, Chantrain G, Remmelink M, Laurent G, Gabius H-J and Saussez S: Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res. 32:4499–4505. 2012.PubMed/NCBI
23.	Kindt N, Preillon J, Kaltner H, Gabius H-J, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G and Saussez S: Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol. 139:727–737. 2013. View Article : Google Scholar : PubMed/NCBI
24.	Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ and Saussez S: Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res. 30:3313–3319. 2010.PubMed/NCBI
25.	Cournia Z, Leng L, Gandavadi S, Du X, Bucala R and Jorgensen WL: Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 52:416–424. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, Bucala R, Leng L, Smith N, Lolis E, Trent JO and Mitchell RA: A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 68:7253–7257. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Khurana D, Martin EA, Kasperbauer JL, O’Malley BW Jr, Salomao DR, Chen L and Strome SE: Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck. 23:899–906. 2001. View Article : Google Scholar : PubMed/NCBI
28.	Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G and Body JJ: Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br J Cancer. 91:1703–1710. 2004.PubMed/NCBI
29.	Baron N, Deuster O, Noelker C, Stüer C, Strik H, Schaller C, Dodel R, Meyer B and Bacher M: Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells. J Neurosci Res. 89:711–717. 2011. View Article : Google Scholar : PubMed/NCBI
30.	Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ and Tracey KJ: ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem. 280:36541–36544. 2005. View Article : Google Scholar : PubMed/NCBI
31.	Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R and Vera PL: Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol. 177:8730–8739. 2006. View Article : Google Scholar : PubMed/NCBI
32.	McClelland M, Zhao L, Carskadon S and Arenberg D: Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol. 174:638–646. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Merk M, Baugh J, Zierow S, Leng L, Pal U, Lee SJ, Ebert AD, Mizue Y, Trent JO, Mitchell R, Nickel W, Kavathas PB, Bernhagen J and Bucala R: The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol. 182:6896–6906. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R and Bernhagen J: Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 18:688–703. 2006. View Article : Google Scholar : PubMed/NCBI
35.	Bifulco C, McDaniel K, Leng L and Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des. 14:3790–3801. 2008. View Article : Google Scholar : PubMed/NCBI
36.	Du W, Wright BM, Li X, Finke J, Rini BI, Zhou M, He H, Lal P and Welford SM: Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene. 32:1469–1474. 2013. View Article : Google Scholar : PubMed/NCBI
37.	Liu L, Ji C, Chen J, Li Y, Fu X, Xie Y, Gu S and Mao Y: A global genomic view of MIF knockdown-mediated cell cycle arrest. Cell Cycle. 7:1678–1692. 2008. View Article : Google Scholar : PubMed/NCBI
38.	Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T and Mitchell RA: Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem. 282:29910–29918. 2007. View Article : Google Scholar : PubMed/NCBI
39.	Lee CY, Su MJ, Huang CY, Chen MY, Hsu HC, Lin CY and Tang CH: Macrophage migration inhibitory factor increases cell motility and up-regulates αvβ3 integrin in human chondrosarcoma cells. J Cell Biochem. 113:1590–1598. 2012.PubMed/NCBI